Spruce Biosciences, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Spruce Biosciences, Inc. (SPRB) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$28.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-12
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$16.23M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$12.27M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$14.65M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$8.21M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$38.97M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$53.04M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$47.92M.
- Spruce Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$46.18M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$28.50M 10-Q · filed 2026-08-12 | -$43.14M derived: sum of 3 quarters · filed 2026-08-12 | -$51.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$12.27M 10-Q · filed 2026-05-13 | -$26.91M derived: sum of 2 quarters · filed 2026-05-13 | -$35.12M derived: sum of 3 quarters · filed 2026-05-13 | -$37.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$14.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$22.86M derived: sum of 2 quarters · filed 2026-03-09 | -$24.93M derived: sum of 3 quarters · filed 2026-08-12 | -$38.97M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$8.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$10.28M derived: sum of 2 quarters · filed 2026-08-12 | -$24.32M 10-Q · filed 2025-11-10 | -$47.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$16.11M 10-Q · filed 2026-08-12 | -$39.67M derived: sum of 3 quarters · filed 2026-08-12 | -$48.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$14.04M 10-Q · filed 2026-05-13 | -$37.60M derived: sum of 2 quarters · filed 2026-05-13 | -$46.27M derived: sum of 3 quarters · filed 2026-05-13 | -$55.45M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$23.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$32.23M derived: sum of 2 quarters · filed 2026-03-09 | -$41.41M derived: sum of 3 quarters · filed 2026-03-09 | -$53.04M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$8.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$17.85M derived: sum of 2 quarters · filed 2025-11-10 | -$29.48M 10-Q · filed 2025-11-10 | -$39.43M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$9.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$20.81M 10-Q · filed 2025-08-14 | -$30.76M derived: sum of 3 quarters · filed 2025-08-14 | -$43.11M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$11.63M 10-Q · filed 2025-05-06 | -$21.57M derived: sum of 2 quarters · filed 2025-05-06 | -$33.93M derived: sum of 3 quarters · filed 2025-05-06 | -$46.75M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$22.30M derived: sum of 2 quarters · filed 2025-04-15 | -$35.13M derived: sum of 3 quarters · filed 2025-04-15 | -$47.92M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$12.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$25.18M derived: sum of 2 quarters · filed 2024-11-12 | -$37.97M 10-Q · filed 2024-11-12 | -$49.11M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$12.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$25.61M 10-Q · filed 2024-08-12 | -$36.76M derived: sum of 3 quarters · filed 2024-08-12 | -$48.16M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$12.79M 10-Q · filed 2024-05-13 | -$23.93M derived: sum of 2 quarters · filed 2024-05-13 | -$35.34M derived: sum of 3 quarters · filed 2024-05-13 | -$47.21M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$11.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$22.55M derived: sum of 2 quarters · filed 2024-03-18 | -$34.42M derived: sum of 3 quarters · filed 2024-03-18 | -$46.18M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$11.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$23.27M derived: sum of 2 quarters · filed 2023-11-13 | -$35.04M 10-Q · filed 2023-11-13 | -$44.22M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$11.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$23.64M 10-Q · filed 2023-08-14 | -$32.82M derived: sum of 3 quarters · filed 2023-08-14 | -$44.27M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$11.76M 10-Q · filed 2023-05-15 | -$20.95M derived: sum of 2 quarters · filed 2023-05-15 | -$32.39M derived: sum of 3 quarters · filed 2023-05-15 | -$44.17M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$20.63M derived: sum of 2 quarters · filed 2023-03-16 | -$32.41M derived: sum of 3 quarters · filed 2023-03-16 | -$42.29M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$11.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$23.22M derived: sum of 2 quarters · filed 2022-11-10 | -$33.11M 10-Q · filed 2022-11-10 | -$41.45M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$11.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$21.66M 10-Q · filed 2022-08-10 | -$30.00M derived: sum of 3 quarters · filed 2022-08-10 | -$39.59M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$9.89M 10-Q · filed 2022-05-11 | -$18.23M derived: sum of 2 quarters · filed 2022-05-11 | -$27.81M derived: sum of 3 quarters · filed 2022-05-11 | -$34.26M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$17.93M derived: sum of 2 quarters · filed 2022-03-14 | -$24.37M derived: sum of 3 quarters · filed 2022-03-14 | -$29.54M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$9.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$16.03M derived: sum of 2 quarters · filed 2021-11-15 | -$21.20M 10-Q · filed 2021-11-15 | -$24.38M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$6.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$11.61M 10-Q · filed 2021-08-10 | -$14.80M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$5.17M 10-Q · filed 2021-05-12 | -$8.35M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$13.09M 10-K · filed 2021-03-22 | ||
| 2019-09-30 | -$9.91M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |